| Predictive testing for inherited mutations in cancer-susceptibility genes |
| FP Li and JF Fraumeni, Jr |
|
JCO Aug 1 1992: 1203–1204.
[PDF]
|
 |
| Serum prostate-specific antigen: the most useful tumor marker |
| GL Andriole |
|
JCO Aug 1 1992: 1205–1207.
[PDF]
|
|
|
Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer |
| |
MA Ritter, EM Messing, TG Shanahan, S Potts, RJ Chappell, and TJ Kinsella |
| |
JCO Aug 1 1992: 1208–1217.
[Abstract]
[PDF]
|
|
|
Combined modality therapy of rectal cancer: decreased acute toxicity with the preoperative approach |
| |
BD Minsky, AM Cohen, N Kemeny, WE Enker, DP Kelsen, B Reichman, L Saltz, ER Sigurdson, and J Frankel |
| |
JCO Aug 1 1992: 1218–1224.
[Abstract]
[PDF]
|
|
|
CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer |
| |
N Masuda, M Fukuoka, Y Kusunoki, K Matsui, N Takifuji, S Kudoh, S Negoro, M Nishioka, K Nakagawa, and M Takada |
| |
JCO Aug 1 1992: 1225–1229.
[Abstract]
[PDF]
|
|
|
Intensive combination chemotherapy, concurrent chest irradiation, and warfarin for the treatment of limited-disease small-cell lung cancer: a Cancer and Leukemia Group B pilot study |
| |
J Aisner, M Goutsou, LH Maurer, R Cooper, P Chahinian, R Carey, A Skarin, R Slawson, MC Perry, and MR Green |
| |
JCO Aug 1 1992: 1230–1236.
[Abstract]
[PDF]
|
|
|
Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study |
| |
GM Strauss, JE Herndon, DD Sherman, DJ Mathisen, RW Carey, NC Choi, VB Rege, C Modeas, and MR Green |
| |
JCO Aug 1 1992: 1237–1244.
[Abstract]
[PDF]
|
|
|
Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study |
| |
AA Forastiere, B Metch, DE Schuller, JF Ensley, LF Hutchins, P Triozzi, JA Kish, S McClure, E VonFeldt, and SK Williamson |
| |
JCO Aug 1 1992: 1245–1251.
[Abstract]
[PDF]
|
|
|
LOPP alternating with EVAP is superior to LOPP alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation trial |
| |
BW Hancock, G Vaughan Hudson, B Vaughan Hudson, MH Bennett, KA MacLennan, JL Haybittle, L Anderson, and DC Linch |
| |
JCO Aug 1 1992: 1252–1258.
[Abstract]
[PDF]
|
|
|
Diffuse small cleaved-cell lymphoma: a heterogeneous disease with distinct immunobiologic subsets |
| |
CP Leith, CM Spier, TM Grogan, G Gonzales, CS Rangel, JA Rybski, M Matzner, and TP Miller |
| |
JCO Aug 1 1992: 1259–1265.
[Abstract]
[PDF]
|
|
|
Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level |
| |
S Vadhan-Raj, HE Broxmeyer, WN Hittelman, NE Papadopoulos, SP Chawla, C Fenoglio, S Cooper, ES Buescher, RW Frenck, Jr, and A Holian |
| |
JCO Aug 1 1992: 1266–1277.
[Abstract]
[PDF]
|
|
|
Effective initial therapy of advanced breast cancer with fluorouracil and high-dose, continuous infusion calcium leucovorin |
| |
KA Margolin, JH Doroshow, SA Akman, LA Leong, RJ Morgan, JW Raschko, G Somlo, and C Blevins |
| |
JCO Aug 1 1992: 1278–1283.
[Abstract]
[PDF]
|
|
|
Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study |
| |
PM Ravdin, S Green, TM Dorr, WL McGuire, C Fabian, RP Pugh, RD Carter, SE Rivkin, JR Borst, and RJ Belt |
| |
JCO Aug 1 1992: 1284–1291.
[Abstract]
[PDF]
|
|
|
Effects of mastectomy versus lumpectomy on emotional adjustment to breast cancer: a prospective study of the first year postsurgery |
| |
C Pozo, CS Carver, V Noriega, SD Harris, DS Robinson, AS Ketcham, A Legaspi, FL Moffat, Jr, and KC Clark |
| |
JCO Aug 1 1992: 1292–1298.
[Abstract]
[PDF]
|
|
|
Infants with neuroblastoma and regional lymph node metastases have a favorable outlook after limited postoperative chemotherapy: a Pediatric Oncology Group study |
| |
RP Castleberry, JJ Shuster, G Altshuler, EI Smith, R Nitschke, N Winick, N McWilliams, V Joshi, and FA Hayes |
| |
JCO Aug 1 1992: 1299–1304.
[Abstract]
[PDF]
|
|
|
Outcomes in low-risk babies treated with half-dose chemotherapy according to the Third National Wilms' Tumor Study |
| |
BW Corn, JW Goldwein, I Evans, and GJ D'Angio |
| |
JCO Aug 1 1992: 1305–1309.
[Abstract]
[PDF]
|
|
|
Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration |
| |
ES Kleinerman, SF Jia, J Griffin, NL Seibel, RS Benjamin, and N Jaffe |
| |
JCO Aug 1 1992: 1310–1316.
[Abstract]
[PDF]
|
|
|
Refinement of clinicopathologic staging for localized soft tissue sarcoma of the extremity: a study of 423 adults |
| |
JJ Gaynor, CC Tan, ES Casper, CF Collin, C Friedrich, M Shiu, SI Hajdu, and MF Brennan |
| |
JCO Aug 1 1992: 1317–1329.
[Abstract]
[PDF]
|
|
|
Role of technetium 99m-labeled monoclonal antibody in the management of melanoma patients |
| |
MJ Blend, SG Ronan, DJ Salk, and TK Gupta |
| |
JCO Aug 1 1992: 1330–1337.
[Abstract]
[PDF]
|
|
|
Sequential chemoimmunotherapy in the treatment of metastatic melanoma |
| |
JM Richards, N Mehta, K Ramming, and P Skosey |
| |
JCO Aug 1 1992: 1338–1343.
[Abstract]
[PDF]
|
|
|
Interferon-alpha, zidovudine, and granulocyte-macrophage colony- stimulating factor: a phase I AIDS Clinical Trials Group study in patients with Kaposi's sarcoma associated with AIDS |
| |
SE Krown, J Paredes, D Bundow, B Polsky, JW Gold, and N Flomenberg |
| |
JCO Aug 1 1992: 1344–1351.
[Abstract]
[PDF]
|
|
|
Phase I trial of thiotepa in combination with recombinant human granulocyte-macrophage colony-stimulating factor |
| |
PJ O'Dwyer, FP LaCreta, R Schilder, S Nash, C McAleer, LL Miller, GR Hudes, and RF Ozols |
| |
JCO Aug 1 1992: 1352–1358.
[Abstract]
[PDF]
|
|
|
Methotrexate pharmacokinetics following administration of recombinant carboxypeptidase-G2 in rhesus monkeys |
| |
PC Adamson, FM Balis, CL McCully, KS Godwin, and DG Poplack |
| |
JCO Aug 1 1992: 1359–1364.
[Abstract]
[PDF]
|
|
| Cisplatin in gynecologic carcinosarcoma |
| PH Willemse, J Bouma, and H Hollema |
|
JCO Aug 1 1992: 1365–1366.
[PDF]
|
|
| Meta-analysis of chemotherapy in multiple myeloma |
| B Djulbegovic, M Blumenreich, T Hadley, and G Joseph |
|
JCO Aug 1 1992: 1366a–1367.
[PDF]
|
|
| Interleukin-2 therapy with or without lymphokine-activated killer-cell infusions for low-grade non-Hodgkin's lymphomas? |
| R Levy, JM Tourani, and JM Andrieu |
|
JCO Aug 1 1992: 1366b.
[PDF]
|
|
| Radiation therapy is better than chemotherapy in early-stage Hodgkin's disease? Not so fast |
| DL Longo, PL Duffey, SM Hubbard, RC Young, and VT DeVita, Jr |
|
JCO Aug 1 1992: 1367–1369.
[PDF]
|
|
| Phase II trials of small-cell lung cancer |
| EL Korn, R Simon, MA Friedman, and TD Moore |
|
JCO Aug 1 1992: 1369–1370.
[PDF]
|
|
| Interpretation of nonsignificant results |
| J Shuster |
|
JCO Aug 1 1992: 1370–1371.
[PDF]
|
|
